Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region

Xiaoqin Li, Xiuli Wang, Hongge Zhu, Chunling Liu*, Xin Zhou, Bing Zhao, Huijie Duan, Jia Yang, Guomin Gu, Yiyi Zhan, Jing Yuan, Kahaer Abuduwaili and Su Qionglu

Abstract

Background: This study was designed to investigate epidermal growth factor receptor (EGFR) mutation types affecting lung cancer treatment in patients in Xinjiang, China. We detected and analyzed differences in the EGFR mutation points of Uighur and Han patients with lung adenocarcinoma. We examined 181 specimens of lung adenocarcinoma tissue embedded with paraffin (76 Uighur and 105 Han patients) for mutations in the EGFR gene in exon 18-21 by the amplification refractory mutation system (ARMS) method. We used the chi-square statistical method to analyze the relationship between mutations and patients’ clinical parameters.

Results: EGFR somatic mutations were detected in 59 of 181 cases (32.6%). The mutation rate was higher in Han patients (45.7%) than in Uighur patients (15.8%) (*P* < 0.001). The main mutation types were the exon 19 deletion and the L858R point mutation in exon 21. In Han patients we found 21 (44.7%) cases of exon 19 deletion, 24 (51.1%) cases of L858R in exon 21, 1 case (2.1%) with mutations in both exon 19 and exon 21, and 1 case (2.1%) with T790 mutation in exon 20. In Uighur patients we found 8 (66.7%) cases of exon 19 deletion and 4 (33.3%) cases of L858R in exon 21.

Conclusions: In comparing these groups, the exon 19 deletion was more common than L858R in exon 21 in Uighur patients. In Han patients, EGFR-sensitive mutations occurred in female, never-smoking patients with well-differentiated tumors; but for Uighur patients only smoking history showed an obvious correlation.

Keywords: Lung adenocarcinoma, EGFR gene mutation, Uighur nationals

Background

Lung cancer has become the leading cause of cancer death worldwide, and the incidence of lung cancer is still on the rise in most countries. Five-year overall survival is only 10% in China. In 2010, an estimated population of 222,500 patients was newly diagnosed with lung cancer and bronchiolar carcinoma (116,750 males and 105,770 females), with 157,300 deaths (86,200 males and 71,100 females) [1].

Recently, molecular targeting therapies against epidermal growth factor receptor (EGFR) have gained increasing recognition in the treatment of lung cancer. Treatment with EGFR tyrosine kinase inhibitor (TKI), e.g. gefitinib and/or erlotinib, in advanced lung cancer has proven itself effective. Multiple clinical studies [2-4] have suggested that female Asian patients with adenocarcinoma who had never smoked had superior efficacy with gefitinib and erlotinib, particularly those with bronchioalveolar carcinoma (BAC). Study results demonstrated that the EGFR tyrosine kinase inhibitor gefitinib (Brand name Iressa©) achieved a response rate of more than 80% in mutant tumors, but was basically ineffective in wild-type tumors without mutations [5]. These results were confirmed post-publication by scientists in other countries. Therefore, guiding EGFR-TKI therapy with EGFR gene status
as predictive molecular marker is an important and practical strategy.

Research shows that EGFR TKI therapy efficacy and EGFR gene mutation status are significantly related to the patients’ ethnic or regional origin and can vary vastly [6]. For example, the exon 21 mutation predominated in Taiwan, and the exon 19 mutation predominated in Guangdong region, but no significant difference was noted between mutations in these two exons in Beijing [7-9]. Most of the studies in this field have focused on populations in Europe and East Asia, but rarely on those in the Middle East and Middle Asia. Xinjiang is located at the junction of the Eurasian continent, and recently the incidence of lung cancer among the local Uighur population has increased year by year. Because EGFR gene mutation status in Uighur patients with lung adenocarcinoma is not known, we designed this study to provide genetic evidence for effective treatment with EGFR-TKI therapy.

Results and Discussion

Patient characteristics

Among 181 lung adenocarcinoma patients, the EGFR mutation rate was 32.6%. In the group of 76 Uighur patients, the EGFR mutation rate was 15.8%; and in the group of 105 Han patients, the mutation rate was 44.8%. For all types of EGFR mutations, the rates were significantly lower in the Uighur patients than in the Han patients (P < 0.001) (Table 1). The two main types of mutation were an exon 19 deletion mutation and L858R (base substitution mutation in codon 858). The percentage of Uighur patients with the exon 19 mutation (66.7%) is higher than that with the exon 21 mutation (33.3%). By contrast, the percentage of Han patients with the exon 19 mutation (44.7%) is slightly lower than that with the exon 21 mutation (51.1%). In the Han group, one patient had both exon 19 and exon 21 mutations (2.1%), and one patient had a T790 mutation in exon 20 (2.1%).

Table 1 EGFR genetic mutation rates in lung adenocarcinoma patients of Uighur and Han ethnic groups

| Ethnic group          | No. of patients | EGFR gene                       | No. of patients with no mutation(%) | No. of patients with mutation(%) | P value  |
|----------------------|----------------|---------------------------------|-------------------------------------|---------------------------------|---------|
| Uighur ethnic group  | 76             | 64(84.2)                        | 12(15.8)                            | P < 0.001                       |         |
| Han ethnic group     | 105            | 58(55.2)                        | 47(44.8)                            |                                 |         |

Table 2 Relationship between EGFR genetic mutation and clinicopathological features in patients of Han ethnic group

| Characteristics | EGFR Mutations | Wild | χ²  | P    |
|-----------------|----------------|------|-----|------|
| Sex             | Male           | 19   | 37  | 5.696| 0.017|
|                 | Female         | 28   | 21  |      |      |
| Age             | ≤65            | 24   | 47  | 0.282| 0.595|
|                 | >65            | 18   | 16  |      |      |
| Smoking         | Yes            | 18   | 34  | 4.289| 0.034|
|                 | No*            | 29   | 24  |      |      |
| pTNM stage      | ≤IIa           | 12   | 13  | 0.354| 0.552|
|                 | >IIa           | 33   | 47  |      |      |
| Tumor differentiation | Well-differentiated | 41 | 35  | 5.861| 0.015|
|                 | Poorly differentiated | 8  | 21  |      |      |

*No smoking is defined as: previous total amount of smoking fewer than 100 cigarettes.
Cancer patients with targeted therapy are associated with lower mutation rates.

Research shows that tumor response to erlotinib is greater in patients with exon 19 mutation compared with patients with exon 21 mutation [18]. In our study, the Uighur group’s mutation rate in exon 19 was higher than that in exon 21 (66.7% vs 33.3%), which is similar to Caucasian population [18]. The Han patients, however, had a slightly lower percentage of exon 19 mutations than exon 21 mutations (44.7% vs. 51.1%). The insertion mutation in exon 20 was not found in the Uighur patients. In the Uighur population the overall effect of EGFR TKI therapy may be better than in the Han population.

Previous reports indicate that EGFR mutation is closely related to age, sex, smoking status, and tumor differentiation. EGFR mutations are common in older, female, non-smoking patients with well-differentiated tumors (especially bronchioalveolar carcinoma) [12,17,18]. Our study’s findings are in accordance with these reports in the Han group: EGFR mutation associated with sex, smoking history, and the degree of tumor differentiation. In the Uighur group, EGFR mutations were correlated with smoking history. The relationship between gene mutation rate and sex or degree of tumor differentiation is not clear, perhaps because the Uighur patients in our study were mostly male and were a small group.

### Conclusion

The EGFR mutation rate in Uighur patients with lung adenocarcinoma is relatively lower than in Han patients, perhaps because of differences in race and region. Uighur patients’ mutation ratio is close to that reported in Caucasian patients, which may be the main reason for poor treatment effectiveness in Uighur patients. Genetic testing for mutations in Uighur patients before treatment could prevent waste of therapeutic resources and could specify targeted drug therapy. In cases of limited resources, where no EGFR gene detection is available and the patient shows intolerance to chemotherapy, smoking history is a reference index. Because of the small number of patients in this study, the relationship between other clinical factors and EGFR mutation remains to be verified by larger-scale studies.

### Methods

#### Study participants and tissue samples

The tissue samples examined in this study were collected by biopsy from November 2011 to January 2014 in Xinjiang Tumor Hospital, and all were diagnosed by pathology. Specimens indicating adenocarcinoma of the lung were paraffin-embedded. The study participants were 76 Uighur patients (49 males and 27 females, ages 46- to 78-years-old, with median age 57 years) and 105

---

**Table 3 Relationship between EGFR genetic mutation and clinicopathological features in patients of Uighur ethnic group**

| Characteristics       | EGFR Mutations | Wild | χ²   | P     |
|-----------------------|----------------|------|------|-------|
| Sex                   |                |      |      |       |
| Male                  | 7              | 42   | 0.235| 0.628 |
| Female                | 5              | 22   |      |       |
| Age                   |                |      |      |       |
| ≤65                   | 8              | 41   | 0.09 | 0.764 |
| >65                   | 4              | 25   |      |       |
| Smoking               |                |      |      |       |
| Yes                   | 3              | 38   | 4.806| 0.028 |
| No*                   | 9              | 26   |      |       |
| pTNM stage            |                |      |      |       |
| ≤IIa                  | 3              | 15   | 0.014| 0.907 |
| >IIa                  | 9              | 49   |      |       |
| Tumor differentiation |                |      |      |       |
| Well-differentiated   | 10             | 36   | 3.102| 0.078 |
| Poorly differentiated  | 2              | 28   |      |       |

*No smoking is defined as: previous total amount of smoking fewer than 100 cigarettes.
Han patients (56 males and 49 females, ages 25- to 85-years-old, with median age 53 years). AJCC TNM staging criteria were used to rate the disease as either stage ≤ IIIa or > IIIa. We used H&E staining to divide the specimens into two groups: well-differentiated tumors and poorly differentiated tumors. The study was reviewed and approved by the Institutional Ethics Committee at Xinjiang Tumor Hospital. All patients signed informed consent forms to participate in this study and to give permission for the use of their tissue.

Sample collection and DNA extraction
We collected samples and extracted DNA from 5- to 8-mm slices of paraffin section, stored at room temperature. The samples were determined by pathologic diagnosis to contain tumor tissue and were preserved for no more than 2 years. We used DNA extraction kit (QIAGEN, Germany), and we dissolved the extracted DNA in Tris-HCl (10 mmol/L, pH 8.0). After sample quality was checked by UV spectrophotometer (Amoy Diagnostics Co. Ltd, China), we added Tris-HCl solution (10 mmol/L, pH 8.0) to adjust DNA concentration to 10 ng/μL and 2 ng/μL standby.

ARMS
Real-time PCR amplified by the amplification refractory mutation system (ARMS) method was used to detect mutations in the EGFR gene exons 18-21. All samples were amplified by Strata Gene MX3000P real-time PCR instrument (Amoy Diagnostics Co. Ltd, China) according to kit instructions, with each test designed with positive and negative control groups. If the Ct value = 0, or Ct value > 30, the experiment will result in wild type. The reaction conditions were as follows: 1 cycle of fluorescence PCR pre-degeneration in 95°C for 5 min; 15 cycles degeneration in 95°C for 25 s, 64°C for 20 s, 72°C for 20 s; and 31 cycles 93°C degeneration for 25 s, 60°C for 35 s, 72°C for 20 s.

Statistical analysis
Data was analyzed using statistical software SPSS 18. Chi-square test was used to compare differences in mutations between the two groups as well as the relationship between patients’ clinical features and EGFR mutations. Probability value was obtained from two-sided tests, with statistical significance defined as P < 0.05.

Abbreviations
ARMS: Amplification refractory mutation system; BAC: Bronchioloalveolar carcinoma; EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CLL and XQL conceived and plan the program. GMG, YYZ, XLW and XZ recorded patients’ information. JY, BZ, JY, KA, SQL and HJD analyzed the data. HGZ contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
None.

Received: 29 December 2014 Accepted: 12 February 2015
Published online: 28 February 2015

References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria J, et al. EGFR tyrosine kinase inhibitors as first-line treatment for advanced non-small-cell lung cancer: a phase II trial of erlotinib in patients with wild-type EGFR tumors. J Clin Oncol. 2005;23:857–65.
3. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857–65.
4. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutational profiles in non-small cell lung cancer. Clin Lung Cancer. 2011;12:339–46.
5. Paes JG, Janne PA, Lee JC, Tracy S, Geugliç H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:497–500.
6. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Srinanpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.
7. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. J Cancer Res. 2014;10:8195–203.
8. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res. 2010;16:4289–94.
9. Qin BM, Chen X, Zhu JD, Pei DO. Identification of EGFR kinase domain mutations among lung cancer patients in China implication for targeted cancer therapy. Cell Res. 2005;15:212–7.
10. Schmid K, Oehl N, Wata F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15:4554–60.
11. Kris M, Johnson B, Kwiatkowski D, Iafate A, Wistuba I, Aonson S, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium. J Clin Oncol. 2011;29:2866–74.
12. Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6:e28204.
13. Han HS, Eom DW, Kim HJ, Kim KH, Shin HM, An JY, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:338–60.
14. Hsu KH, Chen KC, Yang TY, Yeh YC, Chou TY, Chen HY, et al. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol. 2011;6:1066–72.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underly responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.
16. Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2008;59:111–8.
17. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007;67:2325–30.

18. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HP, Kim CH, et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5:1949–52.